Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mechanisms involving deregulated processing of proteins such as amyloid beta (Aβ) oligomerization; tau hyperphosphorylation, prion misfolding; α-synuclein accumulation/lewy body formation, chaperone deregulation, acetylcholine depletion, adenosine 2A (A2A) receptor hyperactivation, secretase deregulation, leucine-rich repeat kinase 2 (LRRK2) mutation and mitochondrial proteinopathies have deeper implications in neurodegenerative disorders.
|
31584139 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-synuclein is a predominantly expressing neuronal protein for understanding the neurodegenerative disorders.
|
31761041 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The misfolding and aggregation of the largely disordered protein, α-synuclein, is a central pathogenic event that occurs in the synucleinopathies; a group of neurodegenerative disorders that includes Parkinson's disease.
|
31848207 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
|
31293044 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
However, there is significant overlap and co-occurrence of α-synuclein and Tau pathologies in a spectrum of neurodegenerative diseases.
|
29738880 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Synucleinopathies are neurodegenerative diseases characterized by the accumulation of either neuronal/axonal or glial insoluble proteinaceous aggregates mainly composed of α-synuclein (α-syn).
|
31693290 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by loss of dopaminergic neurons in substantia nigra region and the presence of α-synuclein aggregates in the striatum and surrounding areas of brain.
|
31834548 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Cell-to-cell transmission of proteopathic alpha-synuclein (α-syn) seeds is increasingly thought to underlie the progression of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and related synucleinopathies.
|
30760864 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a serious neurodegenerative disease and is characterized by abnormal α-synuclein (α-syn) accumulation in Lewy bodies (LB) and Lewy neurites (LN), which makes α-syn an important imaging target for PD.
|
30277753 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is one of the several neurodegenerative diseases where accumulation of aggregated proteins like α-synuclein occurs.
|
30218400 |
2019 |
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data indicate that although aggregation of PAP and SNCA causes severe neurodegenerative diseases, PAP -/- with absence of the Snca does not appear to interrupt the cerebellar architecture development and zone and stripe pattern formation.
|
31509576 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Aggregation of the amyloid-forming α-synuclein (αS) protein is closely associated with the etiology of Parkinson's disease (PD), the most common motor neurodegenerative disorder.
|
31356747 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The α-synuclein transmission hypothesis has profound implications for treatment of what is currently an intractable neurodegenerative disease.
|
31170426 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Several of these pyridine-fused rigid polyheterocycles are shown to bind to Aβ and α-synuclein fibrils, which are associated with neurodegenerative diseases.
|
30862161 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Self-assembly of α-synuclein (α-Syn) is linked with a variety of neurodegenerative diseases collectively called as α-synucleiopathies.
|
31505208 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases.
|
31507618 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Multiple systems atrophy (MSA) is a rare neurodegenerative disorder characterized by the accumulation of α-synuclein in glial cells and neurodegeneration in the striatum, substantia nigra, and cerebellum.
|
30968343 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a common neurodegenerative disease typically associated with the accumulation of α-synuclein.
|
30905782 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a well-known neurodegenerative disorder characterized by dopaminergic (DA) neuron loss and α-synuclein aggregation.
|
30551452 |
2019 |
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Though α-synuclein is expressed predominantly in neurons, α-synuclein aggregates in astrocytes are a common feature in these neurodegenerative diseases.
|
30798354 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
SNCB is thought to function as an antagonist of α-synuclein in neurodegenerative diseases, but the exact role of SNCB remains unclear.
|
31128101 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-Synuclein (α-syn) represents the main component of the amyloid aggregates present in Parkinson's disease and other neurodegenerative disorders, collectively named synucleinopathies.
|
31140178 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is the second most common neurodegenerative disorder and a central role for α-synuclein (αSyn; SNCA) in disease aetiology has been proposed based on genetics and neuropathology.
|
30753527 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, extracellular vesicles (EVs), such as exosomes, have been proposed to play an influential role in the cell-to-cell spread of neurodegenerative diseases, including the intercellular transmission of α-synuclein (α-syn).
|
31555088 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-Synucleinopathies are neurodegenerative diseases that are characterized pathologically by α-synuclein inclusions in neurons and glia.
|
31267577 |
2019 |